VA's Pharmaceutical Prime Vendor Contract Reaches $943.8M in August Spending

Contract Overview

Contract Amount: $943,800,292 ($943.8M)

Contractor: Mckesson Corporation

Awarding Agency: Department of Veterans Affairs

Start Date: 2024-08-01

End Date: 2024-08-31

Sector: Healthcare

Official Description: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2024 AUGUST

Plain-Language Summary

Department of Veterans Affairs obligated $943.8 million to MCKESSON CORPORATION for work described as: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2024 AUGUST Key points: 1. McKesson Corporation holds the contract, indicating a single major supplier for pharmaceuticals. 2. The spending level suggests significant demand for pharmaceutical products within the VA system. 3. Potential risks include over-reliance on one vendor and price fluctuations. 4. The healthcare sector is heavily impacted by pharmaceutical procurement efficiency.

Value Assessment

Rating: good

The contract's value of $943.8M for a single month is substantial. Benchmarking against similar large-scale pharmaceutical prime vendor contracts is necessary to fully assess pricing efficiency, but the scale suggests potential for volume discounts.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This appears to be a sole-source or limited competition contract, likely due to the specialized nature of pharmaceutical prime vendor services. While this can ensure continuity, it may limit price discovery and competitive pressure.

Taxpayer Impact: The VA's ability to secure competitive pricing through this sole-source arrangement directly impacts taxpayer dollars allocated to healthcare for veterans.

Public Impact

Ensures timely access to essential medications for veterans. Supports the VA's healthcare mission by providing a critical supply chain. Potential for price increases if competition is not actively managed.

Waste & Efficiency Indicators

Waste Risk Score: 75 / 10

Warning Flags

  • Sole-source nature limits competitive bidding.
  • High monthly expenditure requires close monitoring.
  • Potential for supply chain disruptions.

Positive Signals

  • Consistent vendor performance.
  • Supports critical healthcare needs.
  • Established relationship with a major supplier.

Sector Analysis

The Department of Veterans Affairs operates within the healthcare sector, with pharmaceutical procurement being a critical component. Benchmarks for similar large-scale pharmaceutical prime vendor contracts would typically involve multi-year agreements with significant annual values, reflecting the scale of national healthcare systems.

Small Business Impact

This contract is awarded to McKesson Corporation, a large prime vendor. There is no immediate indication of significant subcontracting opportunities for small businesses within this specific express report, though the overall PPV program may involve them.

Oversight & Accountability

The Department of Veterans Affairs is responsible for overseeing this contract. Robust oversight is crucial to ensure fair pricing, reliable delivery, and adherence to contract terms, especially given the sole-source nature.

Related Government Programs

  • Department of Veterans Affairs Contracting
  • Department of Veterans Affairs Programs

Risk Flags

  • Sole-source dependency
  • Potential for price inflation
  • Supply chain vulnerability
  • High monthly expenditure concentration

Tags

department-of-veterans-affairs, delivery-order, 100m-plus

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $943.8 million to MCKESSON CORPORATION. EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2024 AUGUST

Who is the contractor on this award?

The obligated recipient is MCKESSON CORPORATION.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $943.8 million.

What is the period of performance?

Start: 2024-08-01. End: 2024-08-31.

What is the historical pricing trend for this Pharmaceutical Prime Vendor contract over the past three years?

Analyzing historical pricing trends is crucial for understanding the long-term value proposition of this sole-source contract. It helps identify any significant price escalations or reductions and assess whether the VA is achieving cost efficiencies comparable to market benchmarks or other federal agencies procuring similar pharmaceutical services.

What are the specific performance metrics and service level agreements (SLAs) in place for McKesson Corporation under this contract?

Understanding the performance metrics and SLAs is vital for assessing contract effectiveness and risk. These define expectations for delivery timeliness, product availability, order accuracy, and inventory management, providing a framework for the VA to hold McKesson accountable and ensure the reliable supply of pharmaceuticals.

How does the VA mitigate the risks associated with a sole-source pharmaceutical prime vendor contract to ensure optimal value for taxpayers?

The VA likely employs several strategies to mitigate sole-source risks, such as rigorous price negotiation, regular performance reviews, market research to establish fair pricing benchmarks, and potentially exploring alternative sourcing strategies for specific high-cost or high-volume drugs to foster competition where feasible.

More Contracts from Mckesson Corporation

View all Mckesson Corporation federal contracts →

Other Department of Veterans Affairs Contracts

View all Department of Veterans Affairs contracts →

Explore Related Government Spending